Schlieren ZH – InSphero has developed a platform that can be used to test drugs in vitro for liver diseases. The company from the Greater Zurich Area has now won a Sino-European Innovation Award for its breakthrough platform.

InSphero was awarded a Sino-European Innovation Award at the 2019 Sino-European Innovation Week in Healthcare Technology (SEIWHT) meeting held in Nanjing, China. According to a press release, it won the award for its 3D InSight Human Liver Disease Platform, which can test in vitro drug efficacy for liver diseases.

InSphero develops 3D microtissues for use during drug development to evaluate the impact of a drug on the human body. Its 3D InSight Human Liver Disease Platform is also based on this 3D microtissue technology and makes it possible to develop drugs in vitro, rather than testing them on animals, to treat certain liver diseases for which no treatment was previously available. These include non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), which can lead to fibrosis, cirrhosis and cancer.

InSphero presented its platform at a session showcasing innovative technologies for the Chinese life science market at SEIWHT, where it earned a second-place award.

“We were proud to see InSphero at SEIWHT representing truly innovative advances being developed and offered by Swiss companies,” said Felix Moesner, CEO of swissnex China, which co-organized SEIWHT together with Technopark Zurich and BioTalk.

InSphero is a spin-off of the University of Zurich (UZH) and the Swiss Federal Institute of Technology in Zurich (ETH) and is headquartered in the Greater Zurich Area.

Contact us

Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?